A delay in the arrival of the rebooted Intellivision video game console. The Intellivision Amico, the modern reboot of the iconic Intellivision video game console, which had been scheduled to hit the market Oct. 10, now is scheduled for release April 15, 2021. Because of production challenges during the pandemic, the company decided to push back the system's launch. Not to do so would have compromised quality assurance, said Intellivision Entertainment CEO Tommy Tallarico during an online event Wednesday. "Ultimately our date is going to be determined by specific quality criteria that the team has defined and not a moment before," he said.
The COVID 19 situation, has rendered the industry into an unprecedented situation. Businesses across the globe are now resorting to plan out new strategies to keep the operations going, to meet clients' demands. Work-from-Home is the new normal for both the employees and the employers to function in a mitigated manner. Twitter on their tweet had suggested their employees, to function through "Work-from-Home", forever, if they want to. This new trend can be easily surmised as being effective for a while to manage operations, but cannot be ruled out as the necessary solution, for satisfying the customers and clients in the long run.
To present a method that automatically segments and quantifies abnormal CT patterns commonly present in coronavirus disease 2019 (COVID-19), namely ground glass opacities and consolidations. In this retrospective study, the proposed method takes as input a non-contrasted chest CT and segments the lesions, lungs, and lobes in three dimensions, based on a dataset of 9749 chest CT volumes. The method outputs two combined measures of the severity of lung and lobe involvement, quantifying both the extent of COVID-19 abnormalities and presence of high opacities, based on deep learning and deep reinforcement learning. The first measure of (PO, PHO) is global, while the second of (LSS, LHOS) is lobe-wise. Evaluation of the algorithm is reported on CTs of 200 participants (100 COVID-19 confirmed patients and 100 healthy controls) from institutions from Canada, Europe and the United States collected between 2002-Present (April 2020).
Researchers from the US National Institute of Standards and Technology found that face masks are causing facial recognition algorithms to fail as much as 50% of the time. In a report, the US National Institute of Standards and Technology found that face masks were thwarting even the most advanced facial recognition algorithms. Error rates varied from 5% to 50%, depending on an algorithm's capabilities. The results are troubling for the facial recognition industry which has been scrambling to develop algorithms that can identify people through their eyes and nose alone as people turn to face masks amid the coronavirus pandemic. The masks have caused trouble for facial recognition software prompting tech companies to adapt.
The dream of creating a machine that emulates human behavior has been an obsession throughout human history. Artificial Intelligence (AI) has been in our minds for many years, since Adam's creation: "God creates him from a moldable material, programs him, and gives him the first instructions (Sánchez-Martín et al. 2007)." Even in Greek mythology with Ovid's account of Pygmalion sculpting a figure of a beautiful woman who is given life for Pygmalion to love her. In Hebrew mythology, the Golem was created with clay and animated to save the inhabitants of a Jewish city. In Norse mythology, the giant Mökkurkálfi or Mistcalf was created from clay to support the troll Hrungnir in his fight against Thor.
The creation of the Global Partnership on Artificial Intelligence (GPAI) reflects the growing interest of states in AI technologies. The initiative, which brings together 14 countries and the European Union, will help participants establish practical cooperation and formulate common approaches to the development and implementation of AI. At the same time, it is a symptom of the growing technological rivalry in the world, primarily between the United States and China. Russia's ability to interact with the GPAI may be limited for political reasons, but, from a practical point of view, cooperation would help the country implement its national AI strategy. The Global Partnership on Artificial Intelligence (GPAI) was officially launched on June 15, 2020, at the initiative of the G7 countries alongside Australia, India, Mexico, New Zealand, South Korea, Singapore, Slovenia and the European Union. According to the Joint Statement from the Founding Members, the GPAI is an "international and multistakeholder initiative to guide the responsible development and use of AI, grounded in human rights, inclusion, diversity, innovation, and economic growth."
AI can save time and money in the search for treatments for emerging diseases, including COVID-19. Artificial intelligence (AI) has been a powerful tool in the search for COVID-19 treatments. In January, BenevolentAI identified a drug for rheumatoid arthritis as a potential therapy for the novel coronavirus. It's now being tested in large-scale trials around the world. AI models and algorithms can save time and money in the search for potential drug leads for emerging diseases.
The COVID-19 pandemic has had a profound impact across industries and healthcare in particular--every aspect of it is undergoing change--from diagnosis to treatment and through the entire continuum of care. This has also created an urgency in the healthcare industry, to look for innovative solutions and a boost to the faster, efficient application of technologies like Artificial Intelligence (AI) and Deep Learning. Pathology is one area which stands to greatly benefit from these applications.
The U.S. Department of Education's Institute of Education Sciences has awarded the National Center for Research on Education Access and Choice (REACH) at Tulane University a $100,000 contract to collect data from approximately 150,000 school websites across the country to see how the nation's education system is responding to the coronavirus pandemic. The project, which will track traditional public schools, charter schools and private schools, aims to quickly answer questions that are critical for understanding how students are learning when school buildings are closed. Key questions include: how many schools are providing any kind of instructional support; which are delivering online instruction; what resources are they offering to students and how do students stay in contact with teachers? "This data will also help answer important questions about equity in the school system, showing how responses differ according to characteristics like spending levels, student demographics, internet access, and if there are differences based on whether it is a private, charter or traditional public school," said REACH National Director Douglas N. Harris, Schlieder Foundation Chair in Public Education and chair of economics at Tulane University School of Liberal Arts. REACH will work in cooperation with Nicholas Mattei, assistant professor of computer science at Tulane University School of Science and Engineering, to create a computer program that will collect data from every school and district website in the country.
The drug, baricitinib, is currently marketed by Eli Lilly to treat rheumatoid arthritis. Now, thanks to AI, it is being tested against COVID-19 in a major randomised-controlled trial in collaboration with the U.S. National Institute for Allergies and Infectious Diseases (NIAID) in combination with remdesivir, an antiviral drug from Gilead Sciences that recently won emergency-use approval for COVID-19. Eli Lilly has now commenced its own independent trial of baricitinib as a therapy for COVID-19 in South America, Europe and Asia.